Peter Zorn stepped down from his positions as chief corporate officer, general counsel and secretary of Albireo Pharma Inc. to pursue other opportunities.
Zorn's departure is effective April 1.
Albireo Pharma chief corporate officer to step down
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Peter Zorn stepped down from his positions as chief corporate officer, general counsel and secretary of Albireo Pharma Inc. to pursue other opportunities.
Zorn's departure is effective April 1.